Combined therapy with myo-inositol and D-chiro-inositol for metabolic and reproductive disorders: a clinical rationale

Background. Polycystic ovary syndrome, insulin resistance, and metabolic disorders are among the most common causes for reduced fertility in reproductive-aged women. Impaired insulin signaling leads to secondary hyperinsulinemia and hyperandrogenism, which contribute to anovulation, irregular menstrual cycles, and reduced fertility. Inositols have recently received considerable attention as physiological insulin sensitizers capable of restoring metabolic and endocrine homeostasis without the use of hormone therapy.

Objective. Present study aimed to substantiate the efficacy and safety of the use of the dietary supplement RitmoZhinel®, which contains myo-inositol and D-chiro-inositol in a physiological ratio of 40:1, as well as alpha-lipoic and folic acids, vitamins D₃, B₅, B₆, C, E, chromium, and manganese.

Results. The analysis of clinical studies and literature data has demonstrated that inositols enhance tissue sensitivity to insulin, reduce androgen levels, restores ovulation and menstrual function. Meta-analyses demonstrate a statistically significant reduction in the HOMAIR index, decreased testosterone levels, and increased ovulation frequency compared with the placebo group. Additional components of the agent provide antioxidant protection, maintain hormonal equilibrium, and potentiate the metabolic effects of inositols.

Conclusion. The body of evidence confirms the pathogenetically substantiated efficacy of a compound as a non-hormonal agent in supporting reproductive health in women with polycystic ovary syndrome and insulin resistance. Its favorable safety profile and good tolerability highlight the potential of this agent as a promising avenue for nutritional support of women’s metabolic and endocrine health.

1. Nestler J. E., Jakubowicz D. J., Reamer P., Gunn R.D., Allan G. Ovulatory and metabolic effects of D-chiro-inositol in women with polycystic ovary syndrome. New England Journal of Medicine. 1999; 340 (17): 1314-1320.

2. Unfer V., Carlomagno G., Dante G., Facchinetti F. Effects of myo-inositol in women with PCOS:a systematic review of randomized controlled trials. Gynecological Endocrinology. 2012; 28 (7): 509-515.

3. Facchinetti F., Bizzarri M., Benvenga S., et al. Results from the International Consensus Conference on Myo-inositol and D-chiro-inositol in obstetrics and gynecology. European Review for Medical and Pharmacological Sciences. 2015; 19 (7): 1316-1326.

4. Pintaudi B., Di Vieste G., Bonomo M. The effectiveness of myo-inositol and D-chiro-inositol treatment in type 2 diabetes. International Journal of Endocrinology. 2016; 2016: 9132052.

5. Unfer V., Nestler J. E., Kamenov Z., Prapas N., Facchinetti F. Effects of inositol (s) in women with PCOS:systematic review and meta-analysis. International Journal of Endocrinology. 2016; 2016: 1849162.

6. Nordio M., Proietti E. The combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters in PCOS. Gynecological Endocrinology. 2012; 28 (12): 969-973.

7. Monastra G., Unfer V., Harrath A. H., Bizzarri M. Combining myo-inositol and D-chiro-inositol improves metabolic and reproductive outcomes in PCOS. International Journal of Molecular Sciences. 2017; 18 (3): 575.

8. Инструкция по применению комплекса РитмоЖинель®. Instructions for use of RitmoZhinel®

9. Genazzani A. D., Lanzoni C., Ricchieri F., Jasonni V. M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in PCOS. Gynecological Endocrinology. 2008; 24 (3): 139-144.

10. Gerli S., Papaleo E., Ferrari A., Di Renzo G. C. Randomized, double-blind placebo-controlled trial of myo-inositol in women with PCOS. European Review for Medical and Pharmacological Sciences. 2007; 11: 347-354.

11. Costantino D., Minozzi G., Minozzi E., Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with PCOS. European Review for Medical and Pharmacological Sciences. 2009; 13 (2): 105-110.

12. Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in PCOS. Journal of Ovarian Research. 2011; 4: 14.

13. Bizzarri M., Fuso A., Dinicola S., Cucina A., Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositols in insulin signaling. Expert Opinion on Drug Metabolism & Toxicology. 2016; 12 (10): 1181-1196.

14. Bevilacqua A., Bizzarri M. Physiological role of inositols in insulin signaling. Endocrine. 2018; 59 (3): 441-449.

15. Fruzzetti F., Perini D., Russo M., et al. Myo-inositol effects on ovarian function and metabolic factors in PCOS. Gynecological Endocrinology. 2017; 33 (9): 698-703.

16. Ciotta L., Stracquadanio M., Pagano I., Carbonaro A., Palumbo M. Effects of myo-inositol supplementation on oocyte quality. European Review for Medical and Pharmacological Sciences. 2011; 15 (5): 509-514.

17. Artini P.G., Di Berardino O.M., Papini F., et al. Endocrine and clinical effects of myo-inositol administration in PCOS. Gynecological Endocrinology. 2013; 29 (4): 375-379.

18. Masharani U., Gjerde C., Evans J. L., et al. Alpha-lipoic acid improves insulin sensitivity in patients with metabolic disorders. Diabetes Care. 2011; 34 (2): 1-6.

19. Genazzani A. D., Santagni S., Rattighieri E., et al. Myo-inositol administration improves insulin resistance in perimenopausal women. Gynecological Endocrinology. 2013; 29 (10):1-5.

20. Croze M. L., Soulage C.O. Potential role and therapeutic interests of myoinositol in metabolic diseases. Biochimie. 2013; 95 (10): 1811-1827.

21. Larner J. D-chiro-inositol in insulin action and insulin resistance. Molecular Medicine. 2002; 8 (9): 543-552.

22. Chiu T. T. Y., Rogers M. S., Law E. L. K., Briton-Jones C. M., Cheung L. P., Haines C. J. Effects of myo-inositol on oocyte quality in IVF cycles. Human Reproduction. 2002; 17 (6): 1591-1596.

23. Baillargeon J. P., Iuorno M. J., Nestler J. E. Insulin sensitizers for PCOS. Fertility and Sterility. 2003; 79 (3): 1-8.

24. Papaleo E., Unfer V., Baillargeon J. P., Fusi F., Occhi F., De Santis L. Myo-inositol in assisted reproduction. Reproductive BioMedicine Online. 2009; 19 (3): 1-7. 25. Dinicola S., Chiu T. T. Y., Unfer V., Carlomagno G., Bizzarri M. The rationale of the myo-inositol and D-chiro-inositol combination. International Journal of Endocrinology. 2014; 2014: 1-9.